GlassScriptPhysician profile
Saumikumar S Karavadia
NPI 1376747162
$49,802.98
in general payments reported to CMS, 2019-2025
55 companies · $9,204 in 2025
The $9,204 reported for 2025 was more than what 94% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,608 · 2020: $8,019 · 2021: $2,148 · 2022: $10K · 2023: $7,113 · 2024: $8,289 · 2025: $9,204.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Food and Beverage: $8,210 · Education: $1,206 · Travel and Lodging: $1,134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,055.00 |
| Food and Beverage | $8,210.39 |
| Education | $1,205.59 |
| Travel and Lodging | $1,134.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $29,193.46 | 2019-2025 | Xtandi, Myrbetriq |
| Pfizer INC. | $4,557.71 | 2019-2025 | |
| Intuitive Surgical, INC. | $1,901.37 | 2023 | Da Vinci Surgical System, Da Vinci Sp |
| Astellas Pharma Global Development | $1,596.00 | 2022 | |
| Janssen Biotech, INC. | $1,522.56 | 2019-2025 | Erleada, Akeega, Rybrevant |
| Myriad Genetic Laboratories, INC. | $1,311.92 | 2021-2025 | Prolaris |
| Bayer Healthcare Pharmaceuticals INC. | $1,044.30 | 2021-2025 | |
| Medtronic USA, INC. | $988.71 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $697.09 | 2023-2025 | Gemtesa, Orgovyx |
| Teleflex LLC | $482.18 | 2021-2025 | Barrigel, Urolift, Solesta |
| Urogen Pharma, INC. | $428.71 | 2021-2025 | |
| Axonics, INC. | $421.60 | 2020-2023 | Axonics |
| Olympus America INC. | $404.73 | 2022-2025 | Itind System |
| Astrazeneca Pharmaceuticals LP | $376.90 | 2020-2022 | |
| Ferring Pharmaceuticals INC. | $357.61 | 2024-2025 | Adstiladrin |
Show all 54 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$66,817.72 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saumikumar Karavadia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.